Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A PHASE 2A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH MODERATE TO SEVERE ALOPECIA AREATA WITH A SINGLE-BLIND EXTENSION PERIOD AND A CROSS-OVER OPEN LABEL EXTENSION PERIOD
In the register
The register attaches this trial to Brepocitinib (Priovant Therapeutics), currently at “Phase 2/3” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- Pfizer
- Participants (registry)
- 142
- Start
- December 2016
- Primary completion
- May 2019
- Study completion
- May 2019
- Last registry update
- May 2020
- Countries
- United States, Australia, Canada
Conditions studied: Alopecia Areata
Interventions: PF-06651600, PF-06700841, Placebo
Other trials of Brepocitinib
Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.